BPG is committed to discovery and dissemination of knowledge
Welcome to the World Journal of Gastrointestinal Pharmacology and Therapeutics

The World Journal of Gastrointestinal Pharmacology and Therapeutics (WJGPT) is a leading academic journal devoted to reporting the latest, cutting-edge research progress and findings of basic research and clinical practice in the field of gastrointestinal pharmacology and therapeutics.  It was launched on February 6, 2010 and is published trimonthly (4 issues annually) by BPG, the world's leading professional clinical medical journal publishing company.

We encourage pharmacology and therapeutics specialists worldwide to submit manuscripts to the WJGPT describing their original basic or clinical research findings that are of high academic value and which report new diagnostic techniques or summarize their treatment experiences.

The usual times related to all publication processes of the WJGPT are as follows: (1) From manuscript receipt to peer-review: 2-4 weeks; (2) From initial manuscript acceptance, with revisions, to return of the revised manuscript from the authors: 4-5 weeks; (3) From return of the revised manuscript from the authors to final acceptance: 1-2 weeks; (4) From final acceptance to an article in press: 2 days; and (5) From article in press designation to formal release of the electronic version and all online documentation: 2-9 weeks. The WJGPT’s acceptance rate: 49%.  Submit here >>

2017 Published Issues
2 1
Editors-in-Chief

Hugh J Freeman, FACG,FACP,FRCP (C),MD, Professor

Indexing/Abstracting

PubMed, PubMed Central.

Journal Metrics

There is currently no impact factor.

ISSN

2150-5349 (online)

Editorial
Management of esophageal caustic injury  
Mark Anthony A De Lusong, Aeden Bernice G Timbol, Danny Joseph S Tuazon
World J Gastrointest Pharmacol Ther 8(2):90-98. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.90
Frontier
5-Aminosalicylates to maintain remission in Crohn’s disease: Interpreting conflicting systematic review evidence  
Morris Gordon
World J Gastrointest Pharmacol Ther 8(2):99-102. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.99
Minireviews
Combination therapy for inflammatory bowel disease  
Keith S Sultan, Joshua C Berkowitz, Sundas Khan
World J Gastrointest Pharmacol Ther 8(2):103-113. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.103
Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment  
Giovanni C Actis, Rinaldo Pellicano
World J Gastrointest Pharmacol Ther 8(2):114-119. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.114
Case Control Study
Thiol/disulphide homeostasis in celiac disease  
Mustafa Kaplan, Ihsan Ates, Mahmut Yuksel, Yasemin Ozderin Ozin, Murat Alisik, Ozcan Erel, Ertugrul Kayacetin
World J Gastrointest Pharmacol Ther 8(2):120-126. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.120
Observational Study
Correlation of rapid point-of-care vs send-out fecal calprotectin monitoring in pediatric inflammatory bowel disease  
Alexis Rodriguez, Lauren Yokomizo, Megan Christofferson, Danielle Barnes, Nasim Khavari, K T Park
World J Gastrointest Pharmacol Ther 8(2):127-130. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.127
Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study  
Anna Viola, Giuseppe Costantino, Antonino Carlo Privitera, Fabrizio Bossa, Angelo Lauria, Laurino Grossi, Maria Beatrice Principi, Nicola Della Valle, Maria Cappello
World J Gastrointest Pharmacol Ther 8(2):131-136. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.131
Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world setting  
Huascar Ramos, Pedro Linares, Ester Badia, Isabel Martín, Judith Gómez, Carolina Almohalla, Francisco Jorquera, Sara Calvo, Isidro García, Pilar Conde, Begoña Álvarez, Guillermo Karpman, Sara Lorenzo, Visitación Gozalo, Mónica Vásquez, Diana Joao, Marina de Benito, Lourdes Ruiz, Felipe Jiménez, Federico Sáez-Royuela, Asociación Castellano y Leonesa de Hepatología (ACyLHE)
World J Gastrointest Pharmacol Ther 8(2):137-146. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.137
Randomized Controlled Trial
Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial  
Saurabh Kedia, Vikram Bhatia, Sandeep Thareja, Sushil Garg, Venigalla Pratap Mouli, Sawan Bopanna, Veena Tiwari, Govind Makharia, Vineet Ahuja
World J Gastrointest Pharmacol Ther 8(2):147-154. Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.147